Authors
O'Leary, Donal PeterMyers, Eddie
Moran, Sarah
Browne, Tara-Jane
Harney, Sinead
Kirwan, William O
Affiliation
Department of Colo-rectal Surgery, Cork University Hospital, Wilton, Cork, Ireland, Olearypeter83@hotmail.com.Issue Date
2011-12
Metadata
Show full item recordCitation
Adalimumab therapy-a double-edged sword? 2011, 26 (12):1621-3 Int J Colorectal DisPublisher
SpringerJournal
International journal of colorectal diseaseDOI
10.1007/s00384-010-1114-3PubMed ID
21221606Item Type
ArticleLanguage
enISSN
1432-1262ae974a485f413a2113503eed53cd6c53
10.1007/s00384-010-1114-3
Scopus Count
Collections
Related articles
- [Oligosymptomatic alimentary tract perforation in course of Crohn's disease in patient treated with anti-TNF alfa antibodies].
- Authors: Jałocha Ł, Wojtuń S, Wojtkowiak M, Błaszak A, Dyrla P, Gil J
- Issue date: 2009 May
- Summaries for patients. Adalimumab for the treatment of hidradenitis suppurativa.
- Issue date: 2012 Dec 18
- Anti tumour necrosis factor as risk factor for free perforations in Crohn's disease? A case-control study.
- Authors: Eshuis EJ, Griffioen GH, Stokkers PC, Ubbink DT, Bemelman WA
- Issue date: 2012 May
- What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
- Authors: Han ES, Monk BJ
- Issue date: 2007 Apr
- Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis.
- Authors: Titos Arcos JC, Hallal H, Robles M, Andrade RJ
- Issue date: 2012 May